SpaceX published its landmark S-1 filing on Wednesday, offering the most comprehensive picture of its financials to date. In its top-line figures, the Starlink creator disclosed that it brought in $18 ...

Cerebras' blockbuster IPO turned its two co-founders into billionaires, based on their holdings in the chipmaker. A decade after starting Cerebras, CEO Andrew Feldman and hardware technology chief ...

AI-IPOs are exciting but arriving at a moment when AI‑infrastructure spending is rising so quickly that it is reshaping the U ...

I last wrote on SpaceX (SPACE) on Mar. 16, 2026. The article rated the stock as a buy after a comparison of its business model against the established United Launch Alliance (ULA). Since then, there ...

However, private secondary marketplaces have low liquidity, high fees, and long settlement times. You also need a high net worth to qualify as an accredited investor. The private fund ETFs also charge ...

SpaceX’s expected $75 billion IPO could become the biggest market debut in history, drawing massive investor demand. But other IPOs may struggle to capture investor attention as Elon Musk’s ...

SpaceX’s IPO filing, made public right after market close Wednesday, had something for everyone. For the Elon Musk fans, it revealed that the CEO needs to colonize Mars if he’s to get a big payday in ...

Elon Musk's SpaceX is opening its blockbuster IPO to retail investors, giving everyday traders access to what could become the largest public offering in history. SpaceX has applied to list on the ...

One of the commonly stated reasons why companies stay private is the costs (and legal risks) of being public. One of those costs is preparing quarterly SEC reports. But there are also costs of ...

At the high end of the range, this implies a roughly $49 billion valuation for Cerebras, with the company raising as much as $4.8 billion in proceeds through the offering. That's more than double the ...

Inspire Brands, the owner of fast-food chains Dunkin’, Arby’s and Jimmy John’s, said Friday it had confidentially filed for a US initial public offering, as the consumer IPO market picks up steam ...

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning. The autoimmune- and inflammatory-disease-focused company first ...